• China’s NMPA accepted Sichuan Kelun-Biotech’s sac-TMT with pembrolizumab for review as first-line treatment for advanced non-squamous non-small cell lung cancer.
• The application covers adults with locally advanced or metastatic disease, PD-L1 TPS below 1%, and EGFR-negative, ALK-negative tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261027-12384416), on October 27, 2026, and is solely responsible for the information contained therein.